1
|
Zhang X, Lin Y, Hosmane NS, Zhu Y. Nanostructured boron agents for boron neutron capture therapy: a review of recent patents. MEDICAL REVIEW (2021) 2023; 3:425-443. [PMID: 38283251 PMCID: PMC10811353 DOI: 10.1515/mr-2023-0013] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/23/2023] [Accepted: 06/16/2023] [Indexed: 01/30/2024]
Abstract
Boron neutron capture therapy (BNCT) is a potential radiation therapy modality for cancer, and tumor-targeted stable boron-10 (10B) delivery agents are an important component of BNCT. Currently, two low-molecular-weight boron-containing compounds, sodium mercaptoundecahydro-closo-dodecaborate (BSH) and boronophenylalanine (BPA), are mainly used in BNCT. Although both have suboptimal tumor selectivity, they have shown some therapeutic benefit in patients with high-grade glioma and several other tumors. To improve the efficacy of BNCT, great efforts have been devoted for the development of new boron delivery agents with better uptake and favorable pharmacokinetic profiles. This article reviews the application and research progress of boron nanomaterials as boron carriers in boron neutron capture therapy and hopes to stimulate people's interest in nanomaterial-based delivery agents by summarizing various kinds of boron nanomaterial patents disclosed in the past decade.
Collapse
Affiliation(s)
- Xiyin Zhang
- Shenzhen HEC Industrial Development Co., Ltd., Shenzhen, Guangdong Province, China
| | - Yusheng Lin
- Shenzhen HEC Industrial Development Co., Ltd., Shenzhen, Guangdong Province, China
| | - Narayan S. Hosmane
- Department of Chemistry and Biochemistry, Northern Illinois University, DeKalb, IL, USA
| | - Yinghuai Zhu
- Sunshine Lake Pharma Co. Ltd, Dongguan, Guangdong Province, China
| |
Collapse
|
2
|
Olaiz N, Monti Hughes A, Pozzi ECC, Thorp S, Curotto P, Trivillin VA, Ramos PS, Palmieri MA, Marshall G, Schwint AE, Garabalino MA. Enhancement in the Therapeutic Efficacy of In Vivo BNCT Mediated by GB-10 with Electroporation in a Model of Oral Cancer. Cells 2023; 12:cells12091241. [PMID: 37174642 PMCID: PMC10177359 DOI: 10.3390/cells12091241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2023] [Revised: 04/17/2023] [Accepted: 04/20/2023] [Indexed: 05/15/2023] Open
Abstract
Boron neutron capture therapy (BNCT) combines preferential tumor uptake of 10B compounds and neutron irradiation. Electroporation induces an increase in the permeability of the cell membrane. We previously demonstrated the optimization of boron biodistribution and microdistribution employing electroporation (EP) and decahydrodecaborate (GB-10) as the boron carrier in a hamster cheek pouch oral cancer model. The aim of the present study was to evaluate if EP could improve tumor control without enhancing the radiotoxicity of BNCT in vivo mediated by GB-10 with EP 10 min after GB-10 administration. Following cancerization, tumor-bearing hamster cheek pouches were treated with GB-10/BNCT or GB-10/BNCT + EP. Irradiations were carried out at the RA-3 Reactor. The tumor response and degree of mucositis in precancerous tissue surrounding tumors were evaluated for one month post-BNCT. The overall tumor response (partial remission (PR) + complete remission (CR)) increased significantly for protocol GB-10/BNCT + EP (92%) vs. GB-10/BNCT (48%). A statistically significant increase in the CR was observed for protocol GB-10/BNCT + EP (46%) vs. GB-10/BNCT (6%). For both protocols, the radiotoxicity (mucositis) was reversible and slight/moderate. Based on these results, we concluded that electroporation improved the therapeutic efficacy of GB-10/BNCT in vivo in the hamster cheek pouch oral cancer model without increasing the radiotoxicity.
Collapse
Affiliation(s)
- Nahuel Olaiz
- Departamento de Física, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires (UBA), Pabellón I, Ciudad Universitaria, Buenos Aires C1428EHA, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2270, Buenos Aires C1425FQD, Argentina
| | - Andrea Monti Hughes
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2270, Buenos Aires C1425FQD, Argentina
- Departamento Radiobiología, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Constituyentes (CAC), Av. General Paz 1499, San Martín, Buenos Aires B1650KNA, Argentina
| | - Emiliano C C Pozzi
- Departamento de Reactores de Investigación y Producción, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Ezeiza (CAE), Camino Real Presbítero González y Aragón 15, Buenos Aires B1802AYA, Argentina
| | - Silvia Thorp
- Sub-Gerencia Instrumentación y Control, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Ezeiza (CAE), Camino Real Presbítero González y Aragón 15, Buenos Aires B1802AYA, Argentina
| | - Paula Curotto
- Departamento de Reactores de Investigación y Producción, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Ezeiza (CAE), Camino Real Presbítero González y Aragón 15, Buenos Aires B1802AYA, Argentina
| | - Verónica A Trivillin
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2270, Buenos Aires C1425FQD, Argentina
- Departamento Radiobiología, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Constituyentes (CAC), Av. General Paz 1499, San Martín, Buenos Aires B1650KNA, Argentina
| | - Paula S Ramos
- Departamento Radiobiología, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Constituyentes (CAC), Av. General Paz 1499, San Martín, Buenos Aires B1650KNA, Argentina
| | - Mónica A Palmieri
- Departamento de Biodiversidad y Biología Experimental, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires (UBA), Pabellón II, Ciudad Universitaria, Buenos Aires C1428EHA, Argentina
| | - Guillermo Marshall
- Departamento de Física, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires (UBA), Pabellón I, Ciudad Universitaria, Buenos Aires C1428EHA, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2270, Buenos Aires C1425FQD, Argentina
| | - Amanda E Schwint
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2270, Buenos Aires C1425FQD, Argentina
- Departamento Radiobiología, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Constituyentes (CAC), Av. General Paz 1499, San Martín, Buenos Aires B1650KNA, Argentina
| | - Marcela A Garabalino
- Departamento Radiobiología, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Constituyentes (CAC), Av. General Paz 1499, San Martín, Buenos Aires B1650KNA, Argentina
| |
Collapse
|
3
|
Xiao W, Pan D, Niu Z, Fan Y, Wu S, Wu W. Opportunities and challenges of high-pressure ion exchange chromatography for nuclide separation and enrichment. CHINESE CHEM LETT 2022. [DOI: 10.1016/j.cclet.2022.03.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
4
|
Importance of radiobiological studies for the advancement of boron neutron capture therapy (BNCT). Expert Rev Mol Med 2022; 24:e14. [PMID: 35357286 DOI: 10.1017/erm.2022.7] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Boron neutron capture therapy (BNCT) is a tumour selective particle radiotherapy, based on the administration of boron carriers incorporated preferentially by tumour cells, followed by irradiation with a thermal or epithermal neutron beam. BNCT clinical results to date show therapeutic efficacy, associated with an improvement in patient quality of life and prolonged survival. Translational research in adequate experimental models is necessary to optimise BNCT for different pathologies. This review recapitulates some examples of BNCT radiobiological studies for different pathologies and clinical scenarios, strategies to optimise boron targeting, enhance BNCT therapeutic effect and minimise radiotoxicity. It also describes the radiobiological mechanisms induced by BNCT, and the importance of the detection of biomarkers to monitor and predict the therapeutic efficacy and toxicity of BNCT alone or combined with other strategies. Besides, there is a brief comment on the introduction of accelerator-based neutron sources in BNCT. These sources would expand the clinical BNCT services to more patients, and would help to make BNCT a standard treatment modality for various types of cancer. Radiobiological BNCT studies have been of utmost importance to make progress in BNCT, being essential to design novel, safe and effective clinical BNCT protocols.
Collapse
|
5
|
Garabalino MA, Olaiz N, Portu A, Saint Martin G, Thorp SI, Pozzi ECC, Curotto P, Itoiz ME, Monti Hughes A, Colombo LL, Nigg DW, Trivillin VA, Marshall G, Schwint AE. Electroporation optimizes the uptake of boron-10 by tumor for boron neutron capture therapy (BNCT) mediated by GB-10: a boron biodistribution study in the hamster cheek pouch oral cancer model. RADIATION AND ENVIRONMENTAL BIOPHYSICS 2019; 58:455-467. [PMID: 31123853 DOI: 10.1007/s00411-019-00796-z] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/22/2018] [Accepted: 05/07/2019] [Indexed: 05/17/2023]
Abstract
Boron neutron capture therapy (BNCT) is a promising cancer binary therapy modality that utilizes the nuclear capture reaction of thermal neutrons by boron-10 resulting in a localized release of high- and low-linear energy transfer (LET) radiation. Electrochemotherapy (ECT) is based on electroporation (EP) that induces opening of pores in cell membranes, allowing the entry of compounds. Because EP is applied locally to a tumor, the compound is incorporated preferentially by tumor cells. Based on the knowledge that the therapeutic success of BNCT depends centrally on the boron content in tumor and normal tissues and that EP has proven to be an excellent facilitator of tumor biodistribution of an anti-tumor agent, the aim of this study was to evaluate if EP can optimize the delivery of boronated compounds. We performed biodistribution studies and qualitative microdistribution analyses of boron employing the boron compound sodium decahydrodecaborate (GB-10) + EP in the hamster cheek pouch oral cancer model. Syrian hamsters with chemically induced exophytic squamous cell carcinomas were used. A typical EP treatment was applied to each tumor, varying the moment of application with respect to the administration of GB-10 (early or late). The results of this study showed a significant increase in the absolute and relative tumor boron concentration and optimization of the qualitative microdistribution of boron by the use of early EP + GB-10 versus GB-10 without EP. This strategy could be a tool to improve the therapeutic efficacy of BNCT/GB-10 in vivo.
Collapse
Affiliation(s)
- Marcela A Garabalino
- Departamento de Radiobiología, Comisión Nacional de Energía Atómica, Centro Atómico Constituyentes, Avenida General Paz 1499, B1650KNA, San Martin, Provincia Buenos Aires, Argentina.
| | - Nahuel Olaiz
- Departamento de Sistemas complejos, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Universitaria, Pabellón II, C1428EHA, Ciudad Autónoma De Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| | - Agustina Portu
- Departamento de Radiobiología, Comisión Nacional de Energía Atómica, Centro Atómico Constituyentes, Avenida General Paz 1499, B1650KNA, San Martin, Provincia Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| | - Gisela Saint Martin
- Departamento de Radiobiología, Comisión Nacional de Energía Atómica, Centro Atómico Constituyentes, Avenida General Paz 1499, B1650KNA, San Martin, Provincia Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| | - Silvia I Thorp
- Sub-gerencia Instrumentación y Control, Centro Atómico Ezeiza, Camino Real Presbítero González y Aragón 15, B1802AYA, Ezeiza, Provincia Buenos Aires, Argentina
| | - Emiliano C C Pozzi
- Departamento de Reactores de Investigación y Producción, Centro Atómico Ezeiza, Camino Real Presbítero González y Aragón 15, B1802AYA, Ezeiza, Provincia Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| | - Paula Curotto
- Departamento de Reactores de Investigación y Producción, Centro Atómico Ezeiza, Camino Real Presbítero González y Aragón 15, B1802AYA, Ezeiza, Provincia Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| | - María E Itoiz
- Departamento de Anatomía Patología, Facultad de Odontología, Universidad de Buenos Aires, Marcelo T. de Alvear 2142, C1122AAH, Ciudad Autónoma De Buenos Aires, Argentina
| | - Andrea Monti Hughes
- Departamento de Radiobiología, Comisión Nacional de Energía Atómica, Centro Atómico Constituyentes, Avenida General Paz 1499, B1650KNA, San Martin, Provincia Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| | - Lucas L Colombo
- Instituto de Oncología Angel H. Roffo, Avenida San Martin 5481, C1417DTB, Ciudad Autónoma De Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| | - David W Nigg
- Idaho National Laboratory, 2525 Fremont Ave, Idaho Falls, ID, 83402, USA
| | - Verónica A Trivillin
- Departamento de Radiobiología, Comisión Nacional de Energía Atómica, Centro Atómico Constituyentes, Avenida General Paz 1499, B1650KNA, San Martin, Provincia Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| | - Guillermo Marshall
- Departamento de Sistemas complejos, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Universitaria, Pabellón II, C1428EHA, Ciudad Autónoma De Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| | - Amanda E Schwint
- Departamento de Radiobiología, Comisión Nacional de Energía Atómica, Centro Atómico Constituyentes, Avenida General Paz 1499, B1650KNA, San Martin, Provincia Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| |
Collapse
|
6
|
Garabalino MA, Heber EM, Monti Hughes A, Pozzi ECC, Molinari AJ, Nigg DW, Bauer W, Trivillin VA, Schwint AE. Boron biodistribution for BNCT in the hamster cheek pouch oral cancer model: combined administration of BSH and BPA. Appl Radiat Isot 2013; 88:64-8. [PMID: 24360859 DOI: 10.1016/j.apradiso.2013.11.118] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2012] [Revised: 11/27/2013] [Accepted: 11/28/2013] [Indexed: 11/18/2022]
Abstract
Sodium mercaptoundecahydro-closo-dodecaborate (BSH) is being investigated clinically for BNCT. We examined the biodistribution of BSH and BPA administered jointly in different proportions in the hamster cheek pouch oral cancer model. The 3 assayed protocols were non-toxic, and showed preferential tumor boron uptake versus precancerous and normal tissue and therapeutic tumor boron concentration values (70-85ppm). All 3 protocols warrant assessment in BNCT studies to contribute to the knowledge of (BSH+BPA)-BNCT radiobiology for head and neck cancer and optimize therapeutic efficacy.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Verónica A Trivillin
- National Atomic Energy Commission (CNEA), Argentina; National Research Council (CONICET), Argentina
| | - Amanda E Schwint
- National Atomic Energy Commission (CNEA), Argentina; National Research Council (CONICET), Argentina.
| |
Collapse
|
7
|
Garabalino MA, Heber EM, Monti Hughes A, González SJ, Molinari AJ, Pozzi ECC, Nievas S, Itoiz ME, Aromando RF, Nigg DW, Bauer W, Trivillin VA, Schwint AE. Biodistribution of sodium borocaptate (BSH) for boron neutron capture therapy (BNCT) in an oral cancer model. RADIATION AND ENVIRONMENTAL BIOPHYSICS 2013; 52:351-361. [PMID: 23591915 DOI: 10.1007/s00411-013-0467-8] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/12/2012] [Accepted: 03/23/2013] [Indexed: 06/02/2023]
Abstract
Boron neutron capture therapy (BNCT) is based on selective accumulation of ¹⁰B carriers in tumor followed by neutron irradiation. We previously proved the therapeutic success of BNCT mediated by the boron compounds boronophenylalanine and sodium decahydrodecaborate (GB-10) in the hamster cheek pouch oral cancer model. Based on the clinical relevance of the boron carrier sodium borocaptate (BSH) and the knowledge that the most effective way to optimize BNCT is to improve tumor boron targeting, the specific aim of this study was to perform biodistribution studies of BSH in the hamster cheek pouch oral cancer model and evaluate the feasibility of BNCT mediated by BSH at nuclear reactor RA-3. The general aim of these studies is to contribute to the knowledge of BNCT radiobiology and optimize BNCT for head and neck cancer. Sodium borocaptate (50 mg ¹⁰B/kg) was administered to tumor-bearing hamsters. Groups of 3-5 animals were killed humanely at nine time-points, 3-12 h post-administration. Samples of blood, tumor, precancerous pouch tissue, normal pouch tissue and other clinically relevant normal tissues were processed for boron measurement by optic emission spectroscopy. Tumor boron concentration peaked to therapeutically useful boron concentration values of 24-35 ppm. The boron concentration ratio tumor/normal pouch tissue ranged from 1.1 to 1.8. Pharmacokinetic curves showed that the optimum interval between BSH administration and neutron irradiation was 7-11 h. It is concluded that BNCT mediated by BSH at nuclear reactor RA-3 would be feasible.
Collapse
Affiliation(s)
- Marcela A Garabalino
- Department of Radiobiology, National Atomic Energy Commission-CNEA, Avenida General Paz 1499, B1650KNA, San Martin, Buenos Aires, Argentina
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Kinashi Y, Masunaga S, Nagata K, Suzuki M, Takahashi S, Ono K. A Bystander Effect Observed in Boron Neutron Capture Therapy: A Study of the Induction of Mutations in the HPRT Locus. Int J Radiat Oncol Biol Phys 2007; 68:508-14. [PMID: 17418970 DOI: 10.1016/j.ijrobp.2007.02.002] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2006] [Revised: 01/26/2007] [Accepted: 02/01/2007] [Indexed: 11/19/2022]
Abstract
PURPOSE To investigate bystander mutagenic effects induced by alpha-particles during boron neutron capture therapy, we mixed cells that were electroporated with borocaptate sodium (BSH), which led to the accumulation of (10)B inside the cells, and cells that did not contain the boron compound. The BSH-containing cells were irradiated with alpha-particles produced by the 10B(n,alpha)7Li reaction, whereas cells without boron were affected only by the 1H(n,gamma)2H and 14N(n,rho)14C reactions. METHODS AND MATERIALS The lethality and mutagenicity measured by the frequency of mutations induced in the hypoxanthine-guanine phosphoribosyltransferase locus were examined in Chinese hamster ovary cells irradiated with neutrons (Kyoto University Research Reactor: 5 MW). Neutron irradiation of 1:1 mixtures of cells with and without BSH resulted in a survival fraction of 0.1, and the cells that did not contain BSH made up 99.4% of the resulting cell population. The molecular structures of the mutations were determined using multiplex polymerase chain reactions. RESULTS Because of the bystander effect, the frequency of mutations increased in the cells located nearby the BSH-containing cells compared with control cells. Molecular structural analysis indicated that most of the mutations induced by the bystander effect were point mutations and that the frequencies of total and partial deletions induced by the bystander effect were less than those induced by the original neutron irradiation. CONCLUSION These results suggested that in boron neutron capture therapy, the mutations caused by the bystander effect and those caused by the original neutron irradiation are induced by different mechanisms.
Collapse
Affiliation(s)
- Yuko Kinashi
- Research Reactor Institute, Kyoto University, Osaka, Japan.
| | | | | | | | | | | |
Collapse
|
9
|
Compounds for neutron capture therapy and their distribution in tumors and surrounding tissues of animals (A review). Pharm Chem J 2006. [DOI: 10.1007/s11094-006-0198-0] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
10
|
Koryakin SN, Ul’yanenko SE, Savina EP, Baranov AP, Krivosheev YV, Yadrovskaya VA. Effect of infrared radiation on the pharmacokinetics of 131I-mercaptododecaborate in animals with model tumors. Pharm Chem J 2005. [DOI: 10.1007/s11094-006-0033-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
11
|
Suzuki M, Masunaga S, Kinashi Y, Nagata K, Sakurai Y, Nakamatsu K, Nishimura Y, Maruhashi A, Ono K. Intra-arterial administration of sodium borocaptate (BSH)/lipiodol emulsion delivers B-10 to liver tumors highly selectively for boron neutron capture therapy: experimental studies in the rat liver model. Int J Radiat Oncol Biol Phys 2004; 59:260-6. [PMID: 15093923 DOI: 10.1016/j.ijrobp.2003.12.018] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2003] [Revised: 12/08/2003] [Accepted: 12/15/2003] [Indexed: 11/24/2022]
Abstract
PURPOSE Boron neutron capture therapy (BNCT) is particle radiotherapy with alpha ((4)He) particle and recoiled lithium nucleus ((7)Li) derived from a reaction of boron ((10)B) and thermal neutron. We investigated applying BNCT to malignant liver tumors. The purpose of the present study was to reveal the efficacy for administration of emulsion of a boron compound (sodium borocaptate; BSH) and lipiodol via a hepatic artery using a rat liver tumor model. METHODS AND MATERIALS Rat liver tumors were developed by direct injection of Walker 256 cells into the liver parenchyma. BSH (75 mg/kg)/lipiodol (0.3 mL/kg) emulsion was administered via the hepatic artery. Boron concentrations in the tumors, liver, and blood were measured at 1, 6, and 12 h after administration. Neutron capture radiography (NCR) was taken to confirm the selective accumulation of (10)B in the liver tumors. RESULTS Boron concentrations in the liver tumors and the tumor/liver (T/L) boron concentration ratio at 1, 6, and 12 h after administration of BSH/lipiodol emulsion (concentration: T/L ratio) were 479.2 ppm: 4.0, 197.3 ppm: 14.9, and 96.5 ppm: 6.6, respectively. Highly selective irradiation was clearly demonstrated by the NCR images. CONCLUSIONS Intra-arterial administration of BSH/lipiodol emulsion is effective method for delivering high concentration of (10)B selectively to the liver tumors.
Collapse
Affiliation(s)
- Minoru Suzuki
- Radiation Oncology Research Laboratory, Research Reactor Institute, Kyoto University, Kyoto, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|